Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Journal Articles

TRAIL Engineering Enhances Expanded Cord Blood NK Cell Anti-Leukemic Activity

Mark Gurney, Margaret Twohig, Derya Goksu Helvaci, Eimear O'Reilly, Sarah Brophy, Janusz Krawczyk, David L. Hermanson, Eva Szegezdi, Michael E. O'Dwyer

Blood (2022) 140 (Supplement 1): 10249–10250.

https://doi.org/10.1182/blood-2022-165517

Published: 2022

Journal Articles

Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

Claire L Feerick, Kevin Lynch, Janusz Krawczyk, Michael O'Dwyer, Aideen Ryan

Blood (2021) 138 (Supplement 1): 2664.

https://doi.org/10.1182/blood-2021-152432

Published: 2021

Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy

Blood (2021) 138 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2021-145530

Published: 2021

Journal Articles

Tc Buster Transposon Engineered CLL-1 CAR-NK Cells Efficiently Target Acute Myeloid Leukemia

Mark Gurney, Eimear O'Reilly, Sarah Corcoran, Sarah Brophy, David Hardwicke, Janusz Krawczyk, David Hermanson, Richard W. Childs, Eva Szegezdi, Michael E. O'Dwyer

Blood (2021) 138 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2021-147244

Published: 2021

Journal Articles

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Mohamed Bakri Mohamed, Seán R Millar, Vitaliy Mykytiv, Rose McMorrow, Conan Donnelly, Paul M Walsh, Eamonn O'Leary, Nina Orfali, Philip Murphy, Paul V. Browne, John Quinn, Peter O'Gorman, Ruth Clifford, Ezzat El Hassadi, Oonagh Gilligan, Janusz Krawczyk, Michael E. O'Dwyer, Eva Szegezdi, Mary R Cahill

Blood (2021) 138 (Supplement 1): 1218.

https://doi.org/10.1182/blood-2021-149832

Published: 2021

Journal Articles

Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment

Sukhraj Pal Singh Dhami, MSc, BSc, Andrea Tirincsi, MSc, BSc, Denis V Baev, PhD, Janusz Krawczyk, MD, John Quinn, MD PhD, Eva Szegezdi, PhD

Blood (2018) 132 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2018-99-118619

Published: 2018

Journal Articles

A Validated and Licensed Method of Bone Marrow Aspirate Procurement to Support Advanced Therapy Investigational Medicinal Product (ATIMP) Manufacture

Sean Naughton, BSc, MSc, Veronica McInerney, PhD, Sara-Azhari Mohamed, MD, Sara Finnerty, Margaret Tarpey, BSc, MSc, Amjad Hayat, MBBS, MRCP, PhD FRCPath, Janusz Krawczyk, MD

Blood (2017) 130 (Supplement 1): 5460.

https://doi.org/10.1182/blood.V130.Suppl_1.5460.5460

Published: 2017

Journal Articles

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

John Daly, MSc, Tony Duggan, BSc, Jinsong Hu, PhD, Alessandro Natoni, PhD, Subhashis Sarkar, PhD, Lucy Kirkham-McCarthy, MSc, Cian McEllistrim, MD, Janusz Krawczyk, MD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 1799.

https://doi.org/10.1182/blood.V130.Suppl_1.1799.1799

Published: 2017

Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Blood (2016) 128 (22): 2117.

https://doi.org/10.1182/blood.V128.22.2117.2117

Published: 2016

Journal Articles

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Joy Buckley, M.Sc. B.Sc., Janusz Krawczyk, MD MRCP, Fionnuala Ni Chonchubhair, MSc, BSc., Nelly Besson, PhD, Margaret Tarpey, MSc. BSc., Margaret Murray, MD, F.R.C.Path., F.R.C.P.I. F.F.Path, M.R.C.P. (U.K.), Michael C O'Dwyer, MD FRCPI, FRCPath, Amjad Hayat, MBBS, MRCP, MRCPath, PhD

Blood (2014) 124 (21): 3848.

https://doi.org/10.1182/blood.V124.21.3848.3848

Published: 2014

Journal Articles

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Janusz Krawczyk, MD, MRCP, Sahar Khan, Bushra Ahsan, Larissa Higgins, Enda McGowan, Safa Eltom, Khalid Awad Saeed, Carmelita Gibbons, Karen Maloney, Teresa Meenaghan, Geraldine Walpole, Catriona Collins, Robert Snedker, Moutaz Abdelrahmen, Amjad Hayat, MBBS, PhD, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Margaret Murray, MD, MRCPath, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2013) 122 (21): 5396.

https://doi.org/10.1182/blood.V122.21.5396.5396

Published: 2013

Journal Articles

Multicentre Retrospective Analysis of Rituximab Use in the Treatment of Steroid Resistant Autoimmune Haemolytic Anaemia in Ireland,

Su Wai Maung, MBBS, MRCP(UK), Denis O'Keeffe, MD, MRCPath, Maeve Leahy, MD, MRCPath, Hilary M O'Leary, MBBChBAO, MRCPI, MRCPath, Irfan Khan, Mary Cahill, FRCPath, Oonagh Galligan, FRCPath, Philip Murphy, MD, MRCPath, Janusz Krawczyk, MRCPI, Suzanne McPherson, MRCPI, J F Jackson, FRCPath, Mary Ryan, FRCPath, Brian Hennessy, MRCPath, Aine C Burke, MBBChBAO, MRCPI, Helen Enright, MD, Johnny McHugh, FRCPath

Blood (2011) 118 (21): 3171.

https://doi.org/10.1182/blood.V118.21.3171.3171

Published: 2011

Journal Articles

Increased Activity of the S Phase Kinase Cdc7 Is Associated with Poor Outcome in Diffuse Large B Cell Lymphoma (DLBCL).

Janusz Krawczyk, MB, Caoimhe Egan, MB, Michelle Mulvihill, MB, Mark Webber, MD, Laura Murillo, MD, Helen Ingoldsby, MD, Corrado Santocanale, PhD, Grace Callagy, MB, PhD, MRCPI, FRCPath, Michael C O'Dwyer, MD, FRCPI, FRCPath

Blood (2009) 114 (22): 1914.

https://doi.org/10.1182/blood.V114.22.1914.1914

Published: 2009

NARROW

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

TRAIL Engineering Enhances Expanded Cord Blood NK Cell Anti-Leukemic Activity

Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Tc Buster Transposon Engineered CLL-1 CAR-NK Cells Efficiently Target Acute Myeloid Leukemia

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment

A Validated and Licensed Method of Bone Marrow Aspirate Procurement to Support Advanced Therapy Investigational Medicinal Product (ATIMP) Manufacture

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Multicentre Retrospective Analysis of Rituximab Use in the Treatment of Steroid Resistant Autoimmune Haemolytic Anaemia in Ireland,

Increased Activity of the S Phase Kinase Cdc7 Is Associated with Poor Outcome in Diffuse Large B Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only